Dr Kate Ren
BSc (York), MPhil (Cantab), PhD (Sheffield)
Population Health, School of Medicine and Population Health
Module Leader of Medical statistics
s.ren@sheffield.ac.uk
+44 114 222 0696
+44 114 222 0696
1012/13, Regent Court (ScHARR)
Full contact details
Dr Kate Ren
Population Health, School of Medicine and Population Health
1012/13
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Population Health, School of Medicine and Population Health
1012/13
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
- Profile
-
I joined HEDS in 2011 after completing a PhD in Probability and Statistics specialising in Bayesian methods in clinical trial design at the University Of Sheffield. I specialise in the development and application of Bayesian method in health economics, and the elicitation of experts' beliefs.
New methods paper on evidence synthesis with limited studies
Analysts often default to use a fixed effect model in evidence synthesis because there are too few studies to conduct a random effects model. The choice of which model to use should depend on the objective of the analysis and knowledge of the included studies. We have developed an elicitation framework using empirical evidence and experts' beliefs to overcome the problem of imprecise estimates of the heterogeneity parameter in the absence of sufficient sample data. We have also provided R code for implementing the method. An Open Access manuscript "Incorporating genuine prior information about between-study heterogeneity in random effects pairwise and network meta-analysis" by Ren et al. is available at dx.doi.org/10.1177/0272989X18759488. The online supplemental material provides both R code and BUGS code for implementing the method.
New methods paper on sampling ordered parameters in PSA
In health economic models, uncertain ordered parameters are common, for example, a patient's utility in a healthy state should be higher than in a diseased state. All probabilistic sensitivity analysis samples should exhibit the logical order of the given parameters. Typical sampling approaches lack either statistical or clinical validity. We have developed a new method, the Difference Method approach, which solves this type of problem more effectively than existing approaches. An Open Access manuscript "A new approach for sampling ordered parameters in probabilistic sensitivity analysis" by Ren et al. is available at link.springer.com via dx.doi.org/10.1007/s40273-017-0584-3. The Excel workbook for sampling ordered parameters can be found from the online supplementary material.
- Research interests
-
- Bayesian statistics in clinical trials and health economics
- Network meta-analysis
- Extrapolate time-to-event data
- Eliciting probability distributions
- Value of information analysis
Current/recent projects
- Medically Unexplained Symptoms (MUS): behaviour modification interventions in primary care settings
- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy: Clinical effectiveness systematic review and economic model
- Methods for the use of non-randomised studies in evidence synthesis
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. Medical Decision Making, 38(4), 531-542. View this article in WRRO
- Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
- How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. PharmacoEconomics. View this article in WRRO
- Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 37(4), 377-390. View this article in WRRO
- Assurance calculations for planning clinical trials with time-to-event outcomes. Statistics in Medicine, 33(1), 31-45. View this article in WRRO
- Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 19(42), 1-102. View this article in WRRO
All publications
Journal articles
- Rate of complete spectacle independence with a trifocal intraocular lens: a systematic literature review and meta-analysis. Ophthalmology and Therapy, 12(2), 1157-1171.
- An investigation of the constancy of effect in Cochrane systematic reviews in context with the assumptions for noninferiority trials. BMC Medical Research Methodology, 22(1).
- The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology, 17(3), 385-394.
- Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation, 18. View this article in WRRO
- R and Shiny for cost-effectiveness analyses : why and when? A hypothetical case study. PharmacoEconomics. View this article in WRRO
- How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. PharmacoEconomics, 38(2), 193-204. View this article in WRRO
- Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients : a systematic literature review and network meta-analysis. Journal of Medical Economics. View this article in WRRO
- Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.. International Journal of Technology Assessment in Health Care. View this article in WRRO
- Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(12), 1427-1437. View this article in WRRO
- Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. Medical Decision Making, 38(4), 531-542. View this article in WRRO
- Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(9), 1063-1072. View this article in WRRO
- Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
- Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics. BJGP Open, 1(3). View this article in WRRO
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(7), 717-726. View this article in WRRO
- How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. PharmacoEconomics. View this article in WRRO
- Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 37(4), 377-390. View this article in WRRO
- Complementary and Alternative Medicine for Management of Premature Ejaculation: A Systematic Review. Sexual Medicine, 5(1), e1-e18. View this article in WRRO
- Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. European Urology Focus, 3(1), 119-129. View this article in WRRO
- Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(1), 97-109. View this article in WRRO
- A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
- Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis. Acta Haematologica, 136(1), 23-42. View this article in WRRO
- A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technology Assessment, 20(37), 1-414. View this article in WRRO
- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment, 20(39), 1-326. View this article in WRRO
- Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(3), 245-257. View this article in WRRO
- Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Meta-analysis, and Individual Patient Data Meta-analysis. Academic Emergency Medicine, 21(9), 960-970. View this article in WRRO
- Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins.. Br J Surg, 101(9), 1040-1052. View this article in WRRO
- Clinical and cost-effectiveness of minimally invasive techniques for the treatment of varicosis: Systematic review and economic evaluation. Vasomed, 26(4), 210-211.
- Assurance calculations for planning clinical trials with time-to-event outcomes. Statistics in Medicine, 33(1), 31-45. View this article in WRRO
- What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.. Health Technol Assess, 18(33), 1-120.
- Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.. Pharmacoeconomics, 31(11), 981-990.
- Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation.. Health Technol Assess, 17(48), i-141.
- Living Health Technology Assessment: Issues, Challenges and Opportunities. PharmacoEconomics.
- Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 19(42), 1-102. View this article in WRRO
- Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. Health Technology Assessment, 24(46), 1-490.
Conference proceedings papers
- PRO15 COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US. Value in Health, Vol. 22 (pp S337-S338)
- PRM152 - How to sample ordered parameters in probabilistic sensitivity analysis. Value in Health, Vol. 20(9) (pp A758-A758)
- EVIDENCE SYNTHESIS FOR HEALTH TECHNOLOGY ASSESSMENT WITH LIMITED STUDIES. VALUE IN HEALTH, Vol. 20(9) (pp A770-A770)
- Systematic Review and Meta-Analysis of the Association Between Transfusion Independence (TI) and Overall Survival (OS) in Patients (pts) with Myelodysplastic Syndromes (MDS). Blood, Vol. 124(21) (pp 1934-1934)
Posters
- MT2 Rate of Complete Spectacle Independence With a Trifocal IOL: A Systematic Literature Review and Meta-Analysis.
- PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.
- Evidence synthesis with limited studies. HTAi 2018, Vancouver, Canada.
- Evidence synthesis for health technology assessment with limited studies.. . ISPOR Glasgow 2017.
- PRE-HOSPITAL NON-INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE: A SYSTEMATIC REVIEW AND NETWORK META ANALYSIS.
- A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014).
- Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and network meta-analysis. 999 EMS Research Forum Conference.
Preprints
- Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
- Grants
-
PhD supervision
I am currently co-supervising a PhD student Enass Duro with Professor Steven A Julious on non-inferiority margin setting from indirect comparison.
Please email me at s.ren@sheffield.ac.uk if you would like to consider a PhD programme, and go to the ScHARR PhD pages for more information.
- Teaching interests
-
Joint-module leader of HAR6170 Medical statistics and evidence synthesis. I teach the medical statistics part of HAR6170.